NZ591176A - Pyrrolopyrimidine compounds as cdk inhibitors - Google Patents

Pyrrolopyrimidine compounds as cdk inhibitors

Info

Publication number
NZ591176A
NZ591176A NZ591176A NZ59117609A NZ591176A NZ 591176 A NZ591176 A NZ 591176A NZ 591176 A NZ591176 A NZ 591176A NZ 59117609 A NZ59117609 A NZ 59117609A NZ 591176 A NZ591176 A NZ 591176A
Authority
NZ
New Zealand
Prior art keywords
cancer
pyrrolo
pyrimidine
carboxylic acid
compounds
Prior art date
Application number
NZ591176A
Other languages
English (en)
Inventor
Gilbert Besong
Christopher Thomas Brain
Clinton A Brooks
Original Assignee
Novartis Ag
Astex Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41171100&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ591176(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Astex Therapeutics Ltd filed Critical Novartis Ag
Publication of NZ591176A publication Critical patent/NZ591176A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ591176A 2008-08-22 2009-08-20 Pyrrolopyrimidine compounds as cdk inhibitors NZ591176A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9103708P 2008-08-22 2008-08-22
PCT/EP2009/060793 WO2010020675A1 (en) 2008-08-22 2009-08-20 Pyrrolopyrimidine compounds as cdk inhibitors

Publications (1)

Publication Number Publication Date
NZ591176A true NZ591176A (en) 2012-11-30

Family

ID=41171100

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ591176A NZ591176A (en) 2008-08-22 2009-08-20 Pyrrolopyrimidine compounds as cdk inhibitors

Country Status (48)

Country Link
US (8) US8685980B2 (cg-RX-API-DMAC7.html)
EP (2) EP2331547B1 (cg-RX-API-DMAC7.html)
JP (2) JP5560496B2 (cg-RX-API-DMAC7.html)
KR (2) KR20130140222A (cg-RX-API-DMAC7.html)
CN (2) CN103788100A (cg-RX-API-DMAC7.html)
AR (2) AR073116A1 (cg-RX-API-DMAC7.html)
AU (1) AU2009284098B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0917791B1 (cg-RX-API-DMAC7.html)
CA (1) CA2734802C (cg-RX-API-DMAC7.html)
CL (1) CL2011000306A1 (cg-RX-API-DMAC7.html)
CO (1) CO6341561A2 (cg-RX-API-DMAC7.html)
CR (1) CR20110101A (cg-RX-API-DMAC7.html)
CU (1) CU24062B1 (cg-RX-API-DMAC7.html)
CY (2) CY1115703T1 (cg-RX-API-DMAC7.html)
DK (1) DK2331547T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2011000057A (cg-RX-API-DMAC7.html)
EA (1) EA019094B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP11010843A (cg-RX-API-DMAC7.html)
ES (1) ES2522346T3 (cg-RX-API-DMAC7.html)
FR (1) FR17C1059I2 (cg-RX-API-DMAC7.html)
GE (1) GEP20135785B (cg-RX-API-DMAC7.html)
HN (1) HN2011000542A (cg-RX-API-DMAC7.html)
HR (1) HRP20141018T1 (cg-RX-API-DMAC7.html)
HU (1) HUS1700051I1 (cg-RX-API-DMAC7.html)
IL (1) IL211164A (cg-RX-API-DMAC7.html)
JO (1) JO2924B1 (cg-RX-API-DMAC7.html)
LT (1) LTC2331547I2 (cg-RX-API-DMAC7.html)
LU (1) LUC00048I2 (cg-RX-API-DMAC7.html)
MA (1) MA32555B1 (cg-RX-API-DMAC7.html)
ME (1) ME01282B (cg-RX-API-DMAC7.html)
MX (1) MX2011001879A (cg-RX-API-DMAC7.html)
MY (1) MY150560A (cg-RX-API-DMAC7.html)
NI (1) NI201100042A (cg-RX-API-DMAC7.html)
NL (1) NL300909I2 (cg-RX-API-DMAC7.html)
NO (1) NO2017059I2 (cg-RX-API-DMAC7.html)
NZ (1) NZ591176A (cg-RX-API-DMAC7.html)
PE (1) PE20110419A1 (cg-RX-API-DMAC7.html)
PL (1) PL2331547T3 (cg-RX-API-DMAC7.html)
PT (1) PT2331547E (cg-RX-API-DMAC7.html)
RS (1) RS53574B1 (cg-RX-API-DMAC7.html)
SI (1) SI2331547T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201500017B (cg-RX-API-DMAC7.html)
TN (1) TN2011000062A1 (cg-RX-API-DMAC7.html)
TW (1) TWI468409B (cg-RX-API-DMAC7.html)
UA (1) UA103628C2 (cg-RX-API-DMAC7.html)
UY (2) UY32067A (cg-RX-API-DMAC7.html)
WO (1) WO2010020675A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201100994B (cg-RX-API-DMAC7.html)

Families Citing this family (247)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0917791B1 (pt) 2008-08-22 2022-03-22 Novartis Ag Compostos de pirrolopirimidina como inibidores de cdk, bem como composição farmacêutica e combinação
EP3406260B1 (en) 2009-05-13 2020-09-23 The University of North Carolina at Chapel Hill Cyclin dependent kinase inhibitors and methods of use
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
UY33226A (es) * 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
AU2011240735B2 (en) 2010-04-13 2015-01-29 Novartis Ag Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (CDK4/6) inhibitor and an mTOR inhibitor for treating cancer
EP2606343A4 (en) 2010-08-18 2017-08-16 Life Technologies Corporation Chemical coating of microwell for electrochemical detection device
US8691830B2 (en) 2010-10-25 2014-04-08 G1 Therapeutics, Inc. CDK inhibitors
PL2632467T3 (pl) 2010-10-25 2016-12-30 Inhibitory CDK
US20120115878A1 (en) * 2010-11-10 2012-05-10 John Vincent Calienni Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
CN103501789A (zh) 2010-11-17 2014-01-08 北卡罗来纳大学查珀尔希尔分校 通过抑制增殖性激酶cdk4和cdk6保护肾组织免于局部缺血
AU2014259534B2 (en) * 2011-01-04 2016-05-19 Novartis Ag Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (AMD)
PH12013501436A1 (en) * 2011-01-04 2013-09-09 Novartis Ag Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd)
CN103781480A (zh) * 2011-07-01 2014-05-07 诺华股份有限公司 联合治疗
CN103635189B (zh) 2011-07-01 2016-05-04 诺华股份有限公司 用于治疗癌症的含有cdk4/6抑制剂和pi3k抑制剂的联合治疗
US9498471B2 (en) 2011-10-20 2016-11-22 The Regents Of The University Of California Use of CDK9 inhibitors to reduce cartilage degradation
US9194840B2 (en) 2012-01-19 2015-11-24 Life Technologies Corporation Sensor arrays and methods for making same
CA2868966C (en) 2012-03-29 2021-01-26 Francis Xavier Tavares Lactam kinase inhibitors
US10202392B2 (en) 2012-04-26 2019-02-12 Francis Xavier Tavares Synthesis of lactams
CN104379579B (zh) 2012-06-28 2017-03-08 诺华股份有限公司 吡咯烷衍生物及其作为补体途径调节剂的用途
JP6155332B2 (ja) 2012-06-28 2017-06-28 ノバルティス アーゲー ピロリジン誘導体、および補体経路調節因子としてのその使用
CN104603126B (zh) 2012-06-28 2017-05-31 诺华股份有限公司 吡咯烷衍生物及其作为补体途径调节剂的用途
US9815819B2 (en) 2012-06-28 2017-11-14 Novartis Ag Complement pathway modulators and uses thereof
JP6214647B2 (ja) 2012-06-28 2017-10-18 ノバルティス アーゲー 補体経路モジュレーターおよびその使用
CN104684910B (zh) 2012-07-12 2016-10-12 诺华股份有限公司 补体途经调节剂及其用途
AR091876A1 (es) * 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
EP4119676A1 (en) 2012-08-03 2023-01-18 Foundation Medicine, Inc. Human papilloma virus as predictor of cancer prognosis
EP2742940B1 (en) 2012-12-13 2017-07-26 IP Gesellschaft für Management mbH Fumarate salt of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-l-aza-bicyclo-[2.2.2]octane for adminstration once daily, twice daily or thrice daily
ES2676177T3 (es) * 2012-12-20 2018-07-17 Novartis Ag Una combinación farmacéutica que comprende binimetinib
US20150353542A1 (en) 2013-01-14 2015-12-10 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
ES2798899T3 (es) 2013-02-25 2020-12-14 Novartis Ag Mutación novedosa del receptor de andrógenos
EP2970200A1 (en) 2013-03-13 2016-01-20 Abbvie Inc. Pyridine cdk9 kinase inhibitors
MX2015012386A (es) 2013-03-13 2016-02-03 Abbvie Inc Inhibidores de la cinasa cdk9.
BR112015023078A2 (pt) * 2013-03-14 2017-07-18 Abbvie Inc inibidores de pirrolopirimindina cdk9 quinase
EP2970264A1 (en) 2013-03-14 2016-01-20 AbbVie Inc. Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors
WO2014139328A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors
US20140274896A1 (en) * 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Transient Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation
ES2761406T3 (es) 2013-03-15 2020-05-19 G1 Therapeutics Inc Protección transitoria de células normales durante una quimioterapia
US20140271460A1 (en) 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Highly Active Anti-Neoplastic and Anti-Proliferative Agents
AU2014233805B2 (en) 2013-03-21 2018-10-18 Array Biopharma Inc. Combination therapy comprising a B-Raf inhibitor and a second inhibitor
AU2014253932B2 (en) 2013-04-16 2020-04-30 Memorial Sloan-Kettering Cancer Center Companion diagnostic for CDK4 inhibitors
HRP20211879T1 (hr) 2013-08-14 2022-03-04 Novartis Ag Kombinirana terapija za liječenje raka
JP6479812B2 (ja) * 2013-08-28 2019-03-06 ノバルティス アーゲー 細胞増殖性疾患を治療するためのａｌｋ阻害剤とｃｄｋ阻害剤との組合せ
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
WO2015049325A1 (en) * 2013-10-03 2015-04-09 F. Hoffmann-La Roche Ag Therapeutic inhibitors of cdk8 and uses thereof
US20160257688A1 (en) * 2013-10-24 2016-09-08 Francis Xavier Tavares Process for Synthesis of Lactams
RU2016125133A (ru) * 2013-11-27 2018-01-09 Новартис Аг Комбинированная терапия, включающая применение ингибиторов jak, cdk и pim
US9476853B2 (en) 2013-12-10 2016-10-25 Life Technologies Corporation System and method for forming microwells
EP3082423B1 (en) * 2013-12-20 2024-12-11 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of cdk and erk inhibitors
ES2864352T3 (es) * 2013-12-23 2021-10-13 Novartis Ag Combinaciones farmacéuticas
KR20160100975A (ko) * 2013-12-23 2016-08-24 노파르티스 아게 제약 조합물
US9949976B2 (en) 2013-12-31 2018-04-24 Xuanzhu Pharma Co., Ltd. Kinase inhibitor and use thereof
ES2687477T3 (es) * 2013-12-31 2018-10-25 Xuanzhu Pharma Co., Ltd. Inhibidor de quinasa y su uso
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
KR102442436B1 (ko) 2014-03-14 2022-09-15 노파르티스 아게 Lag-3에 대한 항체 분자 및 그의 용도
SG11201608303QA (en) 2014-04-04 2016-11-29 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
WO2015160986A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015161288A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic lactams for use as anti-neoplastic and anti-proliferative agents
DK3149008T3 (en) * 2014-05-28 2019-04-01 Shanghai Fochon Pharmaceutical Co Ltd Specific protein kinase inhibitors
CN105294737B (zh) * 2014-07-26 2019-02-12 广东东阳光药业有限公司 Cdk类小分子抑制剂的化合物及其用途
EP3191098A4 (en) 2014-09-12 2018-04-25 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
JP6681905B2 (ja) 2014-09-13 2020-04-15 ノバルティス アーゲー Ａｌｋ阻害剤の併用療法
KR20170066546A (ko) 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
EA201790834A1 (ru) 2014-10-14 2018-01-31 Новартис Аг Молекулы антител к pd-l1 и их применение
JP6930913B2 (ja) 2014-10-14 2021-09-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ 炎症を阻害するためのｃｄｋ９及びｂｒｄ４阻害剤の使用法
CA2967595A1 (en) 2014-11-12 2016-05-19 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
US10138250B2 (en) 2014-12-12 2018-11-27 Crystal Pharmatech Co., Ltd. Salt of pyrrolo[2,3-D]pyrimidine compound and novel polymorph of salt
WO2016091221A1 (zh) * 2014-12-12 2016-06-16 苏州晶云药物科技有限公司 吡咯并[2,3-d]嘧啶化合物的盐及盐的新晶型
CN105111215B (zh) * 2014-12-12 2019-06-18 苏州晶云药物科技股份有限公司 一种周期蛋白依赖性激酶抑制剂的晶型及其制备方法
US20160220569A1 (en) * 2015-02-03 2016-08-04 G1 Therapeutics, Inc. CDK4/6 Inhibitor Dosage Formulations For The Protection Of Hematopoietic Stem And Progenitor Cells During Chemotherapy
EA035817B1 (ru) 2015-03-10 2020-08-14 Адуро Байотек, Инк. Композиции и способы для активации сигналинга, зависимого от "гена стимулятора интерферона"
JP2018509448A (ja) 2015-03-25 2018-04-05 ノバルティス アーゲー 組合せ医薬
MX2017013350A (es) 2015-04-16 2018-01-25 Novartis Ag Comprimido de ribociclib.
CN106146515B (zh) 2015-04-17 2020-09-04 常州隆赛医药科技有限公司 新型激酶抑制剂的制备及应用
TWI696617B (zh) * 2015-04-28 2020-06-21 大陸商上海復尚慧創醫藥研究有限公司 特定蛋白質激酶抑制劑
ES2893478T3 (es) 2015-05-29 2022-02-09 Teijin Pharma Ltd Derivado de pirido[3,4-d]pirimidina y sal farmacéuticamente aceptable del mismo
CN105037236B (zh) * 2015-06-04 2017-07-28 苏州明锐医药科技有限公司 瑞博西尼中间体及其制备方法
CN106336412A (zh) * 2015-07-10 2017-01-18 南开大学 作为cdk4/6抑制剂的2-(n-氧化芳环-2基氨基)-吡咯并嘧啶及嘌呤类化合物
CN106699785A (zh) * 2015-07-13 2017-05-24 南开大学 作为CDK4/6抑制剂的2-(N-氧化吡啶-2基氨基)-吡啶并[2,3-d]嘧啶-7-酮类化合物
CN105130992B (zh) * 2015-07-16 2018-02-09 苏州大学 具有激酶抑制活性的含氮杂环化合物、制备方法和用途
EP3316902A1 (en) 2015-07-29 2018-05-09 Novartis AG Combination therapies comprising antibody molecules to tim-3
ES2878188T3 (es) 2015-07-29 2021-11-18 Novartis Ag Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
US20180222982A1 (en) 2015-07-29 2018-08-09 Novartis Ag Combination therapies comprising antibody molecules to pd-1
CN108135905A (zh) 2015-08-28 2018-06-08 诺华股份有限公司 用于治疗癌症的cdk4/6抑制剂lee011、mek1/2抑制剂曲美替尼以及可任选还包括pi3k抑制剂byl719的组合
EP3340986A1 (en) 2015-08-28 2018-07-04 Novartis AG A pharmaceutical combination comprising the pi3k inhibitor alpelisib and the cdk4/6 inhibitor ribociclib, and the use thereof in the treatment/prevention of cancer
CN108348513A (zh) 2015-08-28 2018-07-31 诺华股份有限公司 用于治疗或预防癌症的ribociclib与达拉菲尼的组合
ES2761885T3 (es) * 2015-08-28 2020-05-21 Novartis Ag Combinaciones farmacéuticas que comprenden (a) el inhibidor de la cinasa dependiente de ciclina 4/6 (CDK4/6) LEE011 (= ribociclib) y (b) el inhibidor del receptor del factor de crecimiento epidérmico (EGFR) erlotinib, para el tratamiento o la prevención del cáncer
EP3156406A1 (en) 2015-10-14 2017-04-19 ratiopharm GmbH Crystalline forms of ribociclib free base
MX2018005298A (es) 2015-11-02 2018-06-22 Novartis Ag Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa.
MA43186B1 (fr) 2015-11-03 2022-03-31 Janssen Biotech Inc Anticorps se liant spécifiquement à pd-1 et leurs utilisations
CA3002097A1 (en) 2015-11-12 2017-05-18 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
CN106749259B (zh) * 2015-11-19 2019-02-01 华东师范大学 一种环戊基嘧啶并吡咯类化合物的合成方法
CN106831780A (zh) * 2015-12-03 2017-06-13 南开大学 具有cdk4/6和hdac抑制活性的新型杂环衍生物
WO2017106656A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
CN105541863B (zh) * 2016-02-16 2017-09-05 安纳康科学股份有限公司 噻吩[2,3‑c]吡啶衍生物及其作为CDK激酶抑制剂的用途
US11921116B2 (en) 2016-03-09 2024-03-05 Memorial Sloan Kettering Cancer Center Enigma and CDH18 as companion diagnostics for CDK4 inhibitors
WO2017161253A1 (en) 2016-03-18 2017-09-21 Tufts Medical Center Compositions and methods for treating and preventing metabolic disorders
TWI772291B (zh) * 2016-03-25 2022-08-01 大陸商正大天晴藥業集團股份有限公司 取代的吡咯並嘧啶類ｃｄｋ抑制劑、包含其藥物組合物及其用途
CN107266451B (zh) * 2016-04-07 2021-12-31 上海医药工业研究院 瑞布昔利布中间体的制备方法
JP6921115B2 (ja) * 2016-04-22 2021-08-18 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド サイクリン依存性キナーゼ４／６（ｃｄｋ４／６）阻害剤のｅ３リガーゼリガンドとのコンジュゲーションによるｃｄｋ４／６の分解および使用法
US10835535B2 (en) 2016-05-07 2020-11-17 Shanghai Fochon Pharmaceutical Co., Ltd. Certain protein kinase inhibitors
WO2017211245A1 (zh) * 2016-06-06 2017-12-14 深圳市塔吉瑞生物医药有限公司 一种取代的吡咯并嘧啶化合物及其应用
KR20230109185A (ko) 2016-06-07 2023-07-19 자코바이오 파마슈티칼스 컴퍼니 리미티드 Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
WO2018005533A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Antiproliferative pyrimidine-based compounds
MX2019000200A (es) 2016-07-01 2019-09-26 G1 Therapeutics Inc Agentes antiproliferativos basados en pirimidina.
NZ749275A (en) 2016-07-01 2023-06-30 G1 Therapeutics Inc Synthesis of n-(heteroaryl)-pyrrolo[2,3-d]pyrimidin-2-amines
WO2018005863A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based compounds for the treatment of cancer
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
RU2769251C2 (ru) 2016-08-23 2022-03-29 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Комбинированная терапия для лечения гепатоцеллюлярной карциномы
WO2018051280A1 (en) * 2016-09-15 2018-03-22 Dr. Reddy’S Laboratories Limited Process for preparation of ribociclib, its acid addition salts
EP3515446B1 (en) 2016-09-19 2023-12-20 Novartis AG Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
CA3040815C (en) 2016-10-20 2021-07-20 Steven Martin Evans Anti-proliferative agents for treating pah
WO2018081211A1 (en) * 2016-10-26 2018-05-03 Li George Y Deuterated 7-cyclopentyl-n, n-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7h-pyrrolo[2,3-d]pyrimdine-6-carboxamide
WO2018089518A1 (en) 2016-11-08 2018-05-17 Dana-Farber Cancer Institute, Inc. Compositions and methods of modulating anti-tumor immunity
WO2018094227A1 (en) * 2016-11-17 2018-05-24 The University Of North Carolina At Chapel Hill Alkyl pyrrolopyrimidine analogs and methods of making and using same
EP3541847A4 (en) 2016-11-17 2020-07-08 Seattle Genetics, Inc. COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE
JP6745905B2 (ja) 2016-11-28 2020-08-26 帝人ファーマ株式会社 ピリド［３，４−ｄ］ピリミジン誘導体又はその溶媒和物の結晶
SI3546458T1 (sl) 2016-11-28 2021-03-31 Teijin Pharma Limited Derivati ((piridin-2-il)-amino)pirido(3,4-d)pirimidina in ((piridazin-3-il)amino)pirido(3,4-d)pirimidina kot zaviralci CDK4/6 za zdravljenje npr. revmatoidnega artritisa, arterioskleroze, pljučne fibroze, možganske kapi ali raka
CN117530948A (zh) 2016-12-05 2024-02-09 G1治疗公司 化疗方案期间免疫反应的保持
EA201991622A1 (ru) 2017-01-06 2020-01-23 Г1 Терапьютикс, Инк. Комплексная терапия для лечения рака
JP2020506904A (ja) 2017-01-27 2020-03-05 シグナルアールエックス ファーマシューティカルズ，インコーポレイテッド キナーゼ、ブロモドメイン及びチェックポイント阻害剤としてのチエノピラノン及びフラノピラノン
US11395821B2 (en) 2017-01-30 2022-07-26 G1 Therapeutics, Inc. Treatment of EGFR-driven cancer with fewer side effects
JP2020510671A (ja) 2017-03-03 2020-04-09 シアトル ジェネティックス， インコーポレイテッド グリカン相互作用化合物および使用の方法
EP3595725B1 (en) 2017-03-16 2023-05-03 Eisai R&D Management Co., Ltd. Combination therapies for the treatment of breast cancer
PT3601239T (pt) 2017-03-23 2024-10-24 Jacobio Pharmaceuticals Co Ltd Novos derivados heterocíclicos úteis como inibidores de shp2
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
DK3618875T3 (da) 2017-05-02 2023-07-10 Novartis Ag Kombinationsterapi omfattende en raf-inhibitor og trametinib
CN107118215B (zh) * 2017-05-06 2019-04-05 上海耀大生物科技有限公司 一种治疗乳腺癌药物瑞博西尼中间体的制备方法
CN106946880B (zh) * 2017-05-06 2019-04-26 南京焕然生物科技有限公司 一种制备瑞博西尼中间体的方法
CN107267481A (zh) * 2017-05-09 2017-10-20 上海交通大学医学院附属新华医院 Cdk5抗原表位肽及其应用
CN108929312A (zh) * 2017-05-22 2018-12-04 南开大学 具有cdk或hdac抑制活性的新型苯并杂环联嘧啶抑制剂
CN108929324A (zh) * 2017-05-22 2018-12-04 南开大学 新型1,1-环丙基二酰胺衍生物的制备与应用
TW201906818A (zh) 2017-05-31 2019-02-16 美商５１１製藥公司 新穎氘取代之正子發射斷層掃描（ｐｅｔ）顯影劑及其藥理應用
WO2018218633A1 (en) 2017-06-02 2018-12-06 Beijing Percans Oncology Co. Ltd. Combination therapies for treating cancers
US20200172628A1 (en) 2017-06-22 2020-06-04 Novartis Ag Antibody molecules to cd73 and uses thereof
KR102659211B1 (ko) 2017-06-29 2024-04-18 쥐원 쎄라퓨틱스, 인크. G1t38의 형체 형태 및 그의 제조 방법
JOP20200015A1 (ar) 2017-08-03 2022-10-30 Novartis Ag توليفة علاجية من مثبط كيناز تيروسين egfr من الجيل الثالث ومثبط كيناز يعتمد على سيكلين
US11155545B2 (en) 2017-08-25 2021-10-26 Sicor—Societa Italiana Corticosteroid s.r.l. Ribociclib salts and solid state forms thereof
EP4667588A2 (en) 2017-08-31 2025-12-24 Novartis AG Methods of prognosis and treating cancer patients
CN111164085B (zh) * 2017-09-29 2023-04-04 杭州领业医药科技有限公司 瑞博西林的共晶和瑞博西林单琥珀酸盐的共晶、其制备方法、组合物和用途
CN111386272B (zh) * 2017-10-27 2023-01-06 费森尤斯卡比肿瘤学有限公司 一种改进的瑞博西尼及其盐的制备方法
US11179365B2 (en) 2017-11-16 2021-11-23 Novartis Ag Pharmaceutical combination comprising LSZ102 and ribociclib
MX2020004756A (es) 2017-11-16 2020-08-20 Novartis Ag Terapias de combinacion.
JP7569688B2 (ja) * 2017-12-22 2024-10-18 ハイバーセル，インコーポレイテッド ホスファチジルイノシトールリン酸キナーゼ阻害剤としてのアミノピリジン誘導体
WO2019123364A1 (en) 2017-12-22 2019-06-27 Shilpa Medicare Limited Novel polymorphs of ribociclib mono succinate
US10519136B2 (en) * 2017-12-29 2019-12-31 Accutar Biotechnology Dual inhibitors of PARP1 and CDK
MY205589A (en) 2018-01-08 2024-10-28 G1 Therapeutics Inc G1t38 superior dosage regimes
CN107936029B (zh) * 2018-01-08 2020-06-30 南京奇可药业有限公司 一种合成瑞博西尼的方法
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
TW201940166A (zh) * 2018-01-29 2019-10-16 美商貝達醫藥公司 作為cdk4及cdk6抑制劑之2h-吲唑衍生物及其治療用途
JP2021514359A (ja) 2018-02-15 2021-06-10 ニューベイション・バイオ・インコーポレイテッドＮｕｖａｔｉｏｎ Ｂｉｏ Ｉｎｃ． キナーゼ阻害剤としての複素環式化合物
WO2019167068A1 (en) 2018-03-01 2019-09-06 Cipla Limited Novel polymorphs of ribociclib succinate
WO2019195959A1 (en) 2018-04-08 2019-10-17 Cothera Biosciences, Inc. Combination therapy for cancers with braf mutation
CA3043066A1 (en) 2018-05-14 2019-11-14 Apotex Inc. Processes for the preparation of ribociclib and intermediates thereof
WO2019222521A1 (en) * 2018-05-16 2019-11-21 G1 Therapeutics, Inc. Cdk inhibitors for the treatment of neoplastic disorders
CN108558745A (zh) * 2018-05-17 2018-09-21 苏州莱克施德药业有限公司 一种帕博西林中间体的合成方法
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
JP7359783B2 (ja) 2018-06-05 2023-10-11 クリネティックス ファーマシューティカルズ，インク． メラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニストおよびその使用
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
MX2021000895A (es) 2018-07-27 2021-08-24 California Inst Of Techn Inhibidores de cinasas dependientes de ciclinas (cdk) y usos de los mismos.
BR112021002622A2 (pt) 2018-08-13 2021-05-11 Beijing Percans Oncology Co. Ltd. biomarcadores para terapia de câncer
EP3840756B1 (en) 2018-08-24 2025-11-05 Pharmacosmos Holding A/S Improved synthesis of 1,4-diazaspiro[5.5]undecan-3-one
JP2022500458A (ja) * 2018-09-13 2022-01-04 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッドChia Tai Tianqing Pharmaceutical Group Co., Ltd. 置換ピロロピリミジン系ｃｄｋ阻害剤の塩とその結晶および使用
CN112839935A (zh) 2018-09-26 2021-05-25 北京加科思新药研发有限公司 可用作shp2抑制剂的新型杂环衍生物
WO2020084389A1 (en) 2018-10-23 2020-04-30 Lupin Limited Ribociclib intermediate and process for preparation thereof
ES2979163T3 (es) 2018-10-31 2024-09-24 Gilead Sciences Inc Compuestos de 6-azabenzimidazol sustituidos como inhibidores de HPK1
TWI721624B (zh) 2018-10-31 2021-03-11 美商基利科學股份有限公司 經取代之6-氮雜苯并咪唑化合物
BR112021011874A2 (pt) 2018-12-20 2021-09-08 Novartis Ag Regime de dosagem e combinação farmacêutica compreendendo derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona
CN109400612A (zh) * 2018-12-24 2019-03-01 重庆三圣实业股份有限公司 一种瑞博西尼的制备方法及其产品和用途
US20220056037A1 (en) * 2018-12-28 2022-02-24 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
US20230065740A1 (en) * 2018-12-28 2023-03-02 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
KR20210119444A (ko) 2019-01-23 2021-10-05 노파르티스 아게 7-사이클로펜틸-2-(5-피페라진-1-일-피리딘-2-일아미노)-7h-피롤로[2,3-d]피리미딘-6-카복실산 디메틸아미드의 석신산염의 신규한 결정질 형태
MX2021009563A (es) 2019-02-12 2021-09-08 Novartis Ag Combinacion farmaceutica que comprende tno155 y ribociclib.
WO2020165833A1 (en) 2019-02-15 2020-08-20 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
AU2020222346B2 (en) 2019-02-15 2021-12-09 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
KR102898876B1 (ko) 2019-05-05 2025-12-12 제넨테크, 인크. Cdk 억제제
WO2020225827A1 (en) 2019-05-08 2020-11-12 Mylan Laboratories Limited Novel polymorphs of ribociclib succinate
KR102881316B1 (ko) 2019-05-13 2025-11-05 노파르티스 아게 암 치료를 위한 raf 억제제로서의 n-(3-(2-(2-하이드록시에톡시)-6-모르폴리노피리딘-4-일)-4-메틸페닐)-2 (트리플루오로메틸)이소니코틴아미드의 새로운 결정질 형태
CA3136088A1 (en) 2019-05-20 2020-11-26 Matthew T. Burger Mcl-1 inhibitor antibody-drug conjugates and methods of use
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
US12466810B2 (en) * 2019-06-04 2025-11-11 Step Pharma S.A.S. N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylsulfonamido)pyrimidin-4-yl) tetrahydro-2H-pyran-4-carboxamide derivatives and related compounds as human CTPS1 inhibitors for the treatment of proliferative diseases
TW202112767A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
CN112094272A (zh) 2019-06-18 2020-12-18 北京睿熙生物科技有限公司 Cdk激酶抑制剂
AU2020336309A1 (en) 2019-08-26 2022-03-17 Arvinas Operations, Inc. Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
WO2021038590A1 (en) 2019-08-30 2021-03-04 Mylan Laboratories Limited Novel polymorph of ribociclib succinate
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
EP4054583A4 (en) 2019-11-07 2023-10-25 Crinetics Pharmaceuticals, Inc. MELANOCORTIN SUBTYPE 2 RECEPTOR (MC2R) ANTAGONISTS AND THEIR USES
CR20220342A (es) 2019-12-16 2023-01-23 Lunella Biotech Inc Agentes terapéuticos selectivos contra el cáncer inhibidores cdk4/6
US12358920B2 (en) * 2019-12-16 2025-07-15 Lunella Biotech, Inc. Substituted pyrrolo[2,3-d]pyrimidines as selective CDK 4/6 inhibitors
EP4077307B1 (en) 2019-12-18 2025-03-12 Crinetics Pharmaceuticals, Inc. Gem-disubstituted piperidine melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof
CN115175937A (zh) 2019-12-20 2022-10-11 诺华股份有限公司 用于治疗骨髓纤维化和骨髓增生异常综合征的抗TIM-3抗体MBG453和抗TGF-β抗体NIS793与或不与地西他滨或抗PD-1抗体斯巴达珠单抗的组合
WO2021133563A1 (en) 2019-12-23 2021-07-01 Crinetics Pharmaceuticals, Inc. Spirocyclic piperidine melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof
CA3161892A1 (en) 2019-12-23 2021-07-01 Jie Fan Combinations of estrogen receptor degraders and cyclin-dependent kinase inhibitors for treating cancer
EP4126244A4 (en) * 2020-03-27 2024-03-27 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. COMBINATION OF ANTI-HER2 ANTIBODIES AND CDK INHIBITORS FOR TUMOR TREATMENT
EP4140997A4 (en) * 2020-05-12 2023-09-06 Suzhou Alphama Biotechnology Co., Ltd. PYRIDINE ACETAMIDE DERIVATIVE AS CDK INHIBITOR, PREPARATION METHOD AND USE THEREOF
JP2023525100A (ja) 2020-05-12 2023-06-14 ノバルティス アーゲー Ｃｒａｆ阻害剤を含む治療的組み合わせ
WO2021227904A1 (zh) * 2020-05-12 2021-11-18 苏州阿尔脉生物科技有限公司 一种作为cdk9抑制剂的多环酰胺类衍生物、其制备方法及用途
KR20230012547A (ko) 2020-05-19 2023-01-26 쥐원 쎄라퓨틱스, 인크. 의학적 장애의 치료를 위한 시클린-의존성 키나제 억제 화합물
MX2022015567A (es) * 2020-06-11 2023-01-19 Lunella Biotech Inc Productos terapeuticos contra el cancer de inhibidores selectivos de cdk4/6.
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
CA3182346A1 (en) 2020-06-23 2021-12-30 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
US20230271940A1 (en) 2020-08-03 2023-08-31 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CN112375081B (zh) * 2020-11-23 2022-04-12 中国医学科学院医药生物技术研究所 具有抑制CDK4、6或9活性的吡咯[2,3-d]嘧啶衍生物及其制备方法和应用
CR20230283A (es) 2020-11-24 2023-07-27 Novartis Ag Anticuerpos anti-cd48, conjugados de anticuerpo-fármaco, y usos de los mismos
EP4251208A1 (en) 2020-11-24 2023-10-04 Novartis AG Mcl-1 inhibitor antibody-drug conjugates and methods of use
WO2022162122A1 (en) 2021-01-29 2022-08-04 Biotx.Ai Gmbh Genetically verified netosis inhibitor for use in the treatment of a sars-cov2 infection
IL304891A (en) 2021-02-02 2023-10-01 Servier Lab Selective Protech BCL-XL compounds and methods of use
WO2022197798A1 (en) 2021-03-19 2022-09-22 Crinetics Pharmaceuticals, Inc. Melanocortin subtype-2 receptor (mc2r) antagonist for the treatment of disease
EP4313987A2 (en) 2021-04-01 2024-02-07 KRKA, d.d., Novo mesto Process for the preparation of ribociclib and pharmaceutically acceptable salts thereof
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
CN117177752A (zh) 2021-05-05 2023-12-05 诺华股份有限公司 用于治疗mpnst的化合物和组合物
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
AU2022311961A1 (en) 2021-07-16 2023-11-09 Dana-Farber Cancer Institute, Inc. Small molecule cyclin dependent kinase 4/6 (cdk4/6) and ikzf2 (helios) degraders and methods of use thereof
CA3227191A1 (en) 2021-07-26 2023-02-02 Celcuity Inc. 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea (gedatolisib) and its combinations for use in the treatment of cancer
WO2023008885A1 (ko) * 2021-07-27 2023-02-02 보로노이바이오 주식회사 피롤로피리미딘 유도체 화합물 및 이의 용도
TWI848533B (zh) 2022-01-25 2024-07-11 瑞士商諾華公司 瑞博西尼藥物組成物
CN114456180B (zh) * 2022-02-18 2023-07-25 贵州大学 用于治疗和/或预防恶性肿瘤的化合物及药物制剂和应用
EP4504709A4 (en) * 2022-04-08 2025-12-24 Biolexis Therapeutics Inc CDK9 inhibitors
JP2025513028A (ja) 2022-04-08 2025-04-22 バイオレクシス セラピューティクス，インコーポレイティド Ｃｄｋ９阻害剤
JP2025517429A (ja) 2022-05-20 2025-06-05 ノバルティス アーゲー Ｍｅｔ ｂｃｌ－ｘｌ阻害剤抗体－薬物コンジュゲートおよびその使用の方法
AU2023271885A1 (en) 2022-05-20 2024-12-12 Les Laboratoires Servier Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
JP2025530742A (ja) 2022-08-31 2025-09-17 アルビナス・オペレーションズ・インコーポレイテッド エストロゲン受容体分解物質の投与計画
WO2024086361A1 (en) * 2022-10-21 2024-04-25 Novartis Ag Molecular glue degrader compounds and uses thereof
EP4615431A1 (en) 2022-11-11 2025-09-17 Astrazeneca AB Combination therapies for the treatment of cancer
EP4626890A1 (en) 2022-12-01 2025-10-08 KRKA, d.d., Novo mesto Ribociclib salts and formulations thereof
IL322700A (en) 2023-03-10 2025-10-01 Novartis Ag Antibody-drug conjugates that inhibit fennerase and methods of using them
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
CN121057581A (zh) 2023-05-05 2025-12-02 阿斯利康(瑞典)有限公司 用于在治疗乳腺癌中使用的卡帕塞替尼、cdk4/6抑制剂和氟维司群的组合
WO2024235844A1 (en) 2023-05-12 2024-11-21 Institut National de la Santé et de la Recherche Médicale Methods of preventing on-target genotoxicity induced by nucleases
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
CN117069663B (zh) * 2023-08-31 2023-12-26 四川维亚本苑生物科技有限公司 一种瑞博西尼中间体v的合成方法及瑞博西尼的合成方法
WO2025051337A1 (en) 2023-09-06 2025-03-13 Afyx Development A/S Compositions and methods for treating and preventing oral cancer
WO2025080628A1 (en) * 2023-10-10 2025-04-17 Biolexis Therapeutics, Inc. Bifunctional protac and molecular glue compounds and methods of use thereof
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025111450A1 (en) 2023-11-22 2025-05-30 Les Laboratoires Servier Anti-cd74 antibody-drug conjugates and methods of use thereof
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025215536A1 (en) 2024-04-10 2025-10-16 Novartis Ag Macrocyclic panras inhibitors for the treatment of cancer
WO2025219830A1 (en) 2024-04-15 2025-10-23 Novartis Ag Pharmaceutical compositions of ribociclib
WO2025235331A1 (en) * 2024-05-07 2025-11-13 Nikang Therapeutics, Inc. Bifunctional compounds containing pyrazolopyrimidine derivatives for degrading certain cyclin-dependent kinase via ubiquitin proteasome pathway
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
CN120441576B (zh) * 2025-07-08 2025-09-26 山东大学 一种靶向cdk4/6的化合物及其衍生的放射性示踪剂
CN120483984B (zh) * 2025-07-09 2025-10-10 山东大学 一种靶向cdk4/6的分子影像探针标记前体、探针及其制备方法与应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
WO1998004689A1 (en) 1995-07-31 1998-02-05 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
KR20060111716A (ko) * 2002-01-22 2006-10-27 워너-램버트 캄파니 엘엘씨 2-(피리딘-2-일아미노)-피리도[2,3-ｄ]피리미딘-7-온
BR0308232A (pt) 2002-03-07 2004-12-28 Hoffmann La Roche Inibidores de cinase p38 de piridina e pirimidina bicìclicas
ATE469903T1 (de) 2002-09-04 2010-06-15 Schering Corp Zur behandlung von krebserkrankungen geeignete pyrazolopyrimidine
WO2004065378A1 (en) * 2003-01-17 2004-08-05 Warner-Lambert Company Llc 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
CA2537829A1 (en) 2003-09-05 2005-03-17 Neurogen Corporation Heteroaryl fused pyridines, pyrazines and pyrimidines as crf1 receptor ligands
JP4895811B2 (ja) 2003-09-11 2012-03-14 ケミア，インコーポレイテッド サイトカイン阻害剤
US7319102B1 (en) 2003-12-09 2008-01-15 The Procter & Gamble Company Pyrrolo[2,3-d]pyrimidine cytokine inhibitors
JP4989233B2 (ja) 2004-02-14 2012-08-01 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
CN1926140A (zh) 2004-03-05 2007-03-07 大正制药株式会社 吡咯并嘧啶衍生物
WO2005107760A1 (en) 2004-04-30 2005-11-17 Irm Llc Compounds and compositions as inducers of keratinocyte differentiation
WO2006008545A2 (en) 2004-07-22 2006-01-26 Astex Therapeutics Limited Thiazole and isothiazole derivatives as protein kinase inhibitors
WO2006042102A2 (en) 2004-10-05 2006-04-20 Neurogen Corporation Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds
EP1807430B1 (en) 2004-10-29 2014-07-23 Janssen R&D Ireland Hiv inhibiting bicyclic pyrimidine derivatives
US7521446B2 (en) 2005-01-13 2009-04-21 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7723340B2 (en) 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
WO2006074985A1 (en) 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. 5-membered annelated heterocyclic pyrimidines as kinase inhibitors
WO2006091737A1 (en) * 2005-02-24 2006-08-31 Kemia, Inc. Modulators of gsk-3 activity
JP2006241089A (ja) 2005-03-04 2006-09-14 Astellas Pharma Inc ピロロピリミジン誘導体またはその塩
WO2007030438A2 (en) 2005-09-06 2007-03-15 Pharmacopeia, Inc. Aminopurine derivatives for treating neurodegenerative diseases
GB0520164D0 (en) 2005-10-04 2005-11-09 Novartis Ag Organic compounds
WO2007058990A2 (en) 2005-11-14 2007-05-24 Kemia, Inc. Therapy using cytokine inhibitors
BRPI0620151A2 (pt) 2005-12-22 2010-06-29 Wyeth Corp composto; composição farmacêutica; método de tratar ou inibir o crescimento de células tumorais cancerosas em um mamìfero que deste necessita; método; e processo
GB0526246D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
AU2007222982A1 (en) 2006-03-09 2007-09-13 Pharmacopeia, Inc. 8-Heteroarylpurine Mnk2 inhibitors for treating metabolic disorders
CA2651072A1 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
JO3235B1 (ar) 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
EP2231656A1 (en) * 2007-12-19 2010-09-29 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
KR20130066703A (ko) * 2008-02-06 2013-06-20 노파르티스 아게 피롤로［２,３­ｄ］피리미딘 및 티로신 키나제 억제제로서 그의 용도
BRPI0917791B1 (pt) * 2008-08-22 2022-03-22 Novartis Ag Compostos de pirrolopirimidina como inibidores de cdk, bem como composição farmacêutica e combinação
GB0819105D0 (en) 2008-10-17 2008-11-26 Chroma Therapeutics Ltd Pyrrolo-pyrimidine compounds
UY33226A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
AU2011240735B2 (en) 2010-04-13 2015-01-29 Novartis Ag Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (CDK4/6) inhibitor and an mTOR inhibitor for treating cancer

Also Published As

Publication number Publication date
EP2716643A1 (en) 2014-04-09
EA201100355A8 (ru) 2013-09-30
JP5560496B2 (ja) 2014-07-30
TW201014858A (en) 2010-04-16
CN103788100A (zh) 2014-05-14
US20130184285A1 (en) 2013-07-18
TWI468409B (zh) 2015-01-11
AU2009284098A1 (en) 2010-02-25
IL211164A0 (en) 2011-04-28
CU24062B1 (es) 2014-12-26
EA019094B1 (ru) 2014-01-30
CY1115703T1 (el) 2017-01-25
LTC2331547I2 (lt) 2018-09-10
JP5882371B2 (ja) 2016-03-09
US20110152244A1 (en) 2011-06-23
NI201100042A (es) 2011-08-09
FR17C1059I1 (cg-RX-API-DMAC7.html) 2018-02-16
PE20110419A1 (es) 2011-07-13
CR20110101A (es) 2011-06-09
HRP20141018T1 (hr) 2015-02-13
GEP20135785B (en) 2013-03-11
IL211164A (en) 2016-09-29
HUS1700051I1 (hu) 2017-12-28
US20240043428A1 (en) 2024-02-08
UY38935A (es) 2020-12-31
CA2734802C (en) 2016-05-31
MX2011001879A (es) 2011-03-29
US20140135312A1 (en) 2014-05-15
FR17C1059I2 (fr) 2019-01-11
LUC00048I1 (cg-RX-API-DMAC7.html) 2017-11-15
NL300909I2 (nl) 2017-12-19
DK2331547T3 (da) 2014-11-03
CU20110040A7 (es) 2011-12-28
CN102186856B (zh) 2014-09-24
BRPI0917791B1 (pt) 2022-03-22
MA32555B1 (fr) 2011-08-01
LUC00048I2 (cg-RX-API-DMAC7.html) 2018-01-10
ZA201100994B (en) 2011-12-28
KR101353857B1 (ko) 2014-01-21
PL2331547T3 (pl) 2015-01-30
LTPA2017039I1 (lt) 2017-12-11
ME01282B (me) 2013-06-20
US8962630B2 (en) 2015-02-24
DOP2011000057A (es) 2015-11-15
BRPI0917791A2 (pt) 2019-08-13
PT2331547E (pt) 2014-10-29
AU2009284098B2 (en) 2012-03-29
JP2014129361A (ja) 2014-07-10
WO2010020675A1 (en) 2010-02-25
US9416136B2 (en) 2016-08-16
EP2331547B1 (en) 2014-07-30
EP2331547A1 (en) 2011-06-15
EA201100355A1 (ru) 2011-10-31
HK1156625A1 (en) 2012-06-15
SI2331547T1 (sl) 2014-11-28
RS53574B1 (sr) 2015-02-27
KR20130140222A (ko) 2013-12-23
CA2734802E (en) 2010-02-25
US20180155351A1 (en) 2018-06-07
US8415355B2 (en) 2013-04-09
CY2017042I1 (el) 2018-04-04
AR073116A1 (es) 2010-10-13
MY150560A (en) 2014-01-30
US20100105653A1 (en) 2010-04-29
JP2012500785A (ja) 2012-01-12
ECSP11010843A (es) 2011-05-31
CN102186856A (zh) 2011-09-14
CO6341561A2 (es) 2011-11-21
HN2011000542A (es) 2013-10-17
CY2017042I2 (el) 2018-04-04
NO2017059I1 (no) 2017-11-13
CA2734802A1 (en) 2010-02-25
NO2017059I2 (no) 2017-11-13
SMT201500017B (it) 2015-03-05
NL300909I1 (cg-RX-API-DMAC7.html) 2017-11-10
ES2522346T3 (es) 2014-11-14
JO2924B1 (en) 2015-09-15
US8685980B2 (en) 2014-04-01
US20170183352A1 (en) 2017-06-29
CL2011000306A1 (es) 2011-06-24
US20210253578A1 (en) 2021-08-19
UA103628C2 (en) 2013-11-11
AR111763A2 (es) 2019-08-14
KR20110052713A (ko) 2011-05-18
TN2011000062A1 (en) 2012-09-05
UY32067A (es) 2010-03-26

Similar Documents

Publication Publication Date Title
NZ591176A (en) Pyrrolopyrimidine compounds as cdk inhibitors
MX2009010595A (es) Derivados de pirrolopirimidina.
UA95934C2 (ru) Производные пиридиазинона для лечения опухолей
SI2010181T1 (sl) Postopki zdravljenja celičnih proliferacijskih motenj z uporabo pirimidindiaminskih spojin
SG10201900514RA (en) Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
MY156785A (en) Novel phenylimidazole derivative as pde10a enzyme inhibator
TW200740815A (en) P38 MAP kinase inhibitors and methods for using the same
WO2010000364A8 (de) Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
PH12013501940A1 (en) Fused tricyclic dual inhibitors of cdk 4/6 and flt3
UA101611C2 (ru) СОЕДИНЕНИЯ ИМИДАЗО[1,2-а]ПИРИДИНА КАК ИНГИБИТОРЫ ТИРОЗИНКИНАЗЫ РЕЦЕПТОРОВ
CA2603830A1 (en) PYRIDINE [2,3-B] PYRAZINONES
MX2012002480A (es) Inhibidores de jak2 y su uso en el tratamiento de enfermedades mieloproliferativas y cancer.
TW200618800A (en) Heterocyclic compounds
ZA201004368B (en) Pyrazolo [1,5-a] pyrimidines useful as jak2 inhibitors
ZA200701137B (en) Triazolophthalazines
MY153921A (en) Aminopyrazole derivatives
MY150493A (en) Quinazoline derivatives
TW200730174A (en) Chemical compounds
CL2011001445A1 (es) Compuesto 3-(4-cloro-2-fluorobencil)-2-metil-n-(5-metil-1h-pirazol-3-il)-8-(morfolinometil)imidazo[1,2-b]piridazin-6-amina; composicion farmaceutica; y uso en el tratamiento de trastornos mieloproliferantes cronicos y en el tratamiento de glioblastoma, cancer de amama, mieloma multiple, cancer de prostata y leucemias
GEP20115231B (en) 2-amino-7,8-dihydro-6h-pyrido [4,3-d] pyrimidin-5-ones
MX2009010485A (es) Derivados de imidazolidinacarboxamida como inhibidores de lipasas y fosfolipasas.
MY140514A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
TW200728277A (en) Bicyclic derivatives as P38 inhibitors
MX2014008864A (es) Derivados de triazolo[4,5-d]pirimidina.
TW200630374A (en) Thiazolyldihydroindazoles

Legal Events

Date Code Title Description
S883 Correction of error according to section 88(3) (mistake in register caused on part of patentee or applicant)

Free format text: CORRECTION TO INVENTOR (72)

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 20 AUG 2016 BY CPA GLOBAL

Effective date: 20130704

ERR Error or correction

Free format text: THE OWNER HAS BEEN CORRECTED TO 890887, NOVARTIS AG, LICHTSTRASSE 35, CH-4056 BASEL, CH; 1370556, ASTEX THERAPEUTICS LTD, 436 CAMBRIDGE SCIENCE PARK, MILTON ROAD, CAMBRIDGE, CB4 0QA, GB

Effective date: 20140409

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 20 AUG 2019 BY CPA GLOBAL

Effective date: 20140910

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 AUG 2020 BY CPA GLOBAL

Effective date: 20190718

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 AUG 2021 BY CPA GLOBAL

Effective date: 20200716

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 AUG 2022 BY CPA GLOBAL

Effective date: 20210722

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 AUG 2023 BY CPA GLOBAL

Effective date: 20220721

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 AUG 2024 BY CPA GLOBAL

Effective date: 20230720

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 AUG 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20240718

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 AUG 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20250717